Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Industry News

Drug Approvals Surged in 2017. What Does That Mean for Pharma?

Thursday, January 4, 2018   (0 Comments)
Share |

SOURCE

 

Forty-six new drugs cleared the desks of regulators at the Food and Drug Administration last year — the most New Molecular Entities approved since 1996 and more than double the number OK'd in 2016.

And that figure doesn't include the approval of several groundbreaking medicines, including two cell therapies for cancer and the U.S.'s first-ever gene therapy for an inherited disorder, which were given a green light by another office within the FDA.

All told, the stepped-up pace of approvals is good news for biotech and pharma companies, signaling a generally welcoming regulator. 2017's uptick in approvals also suggests the low mark seen in 2016 likely represents an outlier rather than a warning of withering drug pipelines.

 

Read the full article here.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal